ABSTRACT
Background Intrinsic capacity (IC) is a function-related concept that reflects healthy aging. Identifying IC biomarkers is an essential step to slow down functional declines at early stages. ATPase inhibitory factor 1 (IF1) is a multifaceted protein that regulates mitochondrial oxidative phosphorylation (OXPHOS), thereby affecting cellular energy production.
Objective To investigate the association between plasma levels of IF1 and IC changes over four years in community-dwelling older adults.
Methods Community-dwelling older adults aged over 70 years at risk of cognitive decline from the Multidomain Alzheimer Preventive Trial (MAPT Study) were enrolled in this study. A composite IC score was calculated (ranging from 0 to 100; higher is better) over time using data on the following IC domains: locomotion, psychological dimension, cognition, vitality, and sensory ability (vision and hearing; assessed over one year only). Plasma levels of IF1 were assessed one year after the beginning of the study. Mixed-model linear regression adjusted for confounders was performed.
Results A total of 1090 participants had usable IF1 values (mean age 75.3 ± 4.4 years; 64% females). The mean values of plasma IF1 and IC (4 domains) were 565.62 ± 251.92 ng/mL and 74.85 ± 8.43, respectively. Compared to the lowest quartile, low- and high-intermediate IF1 quartiles were cross-sectionally associated with greater composite IC scores of four domains (βlow-intermediate, 1.33; 95% CI 0.06– 2.60 and βhigh-intermediate, 1.78; 95% CI 0.49–3.06), and the highest quartile associated with a slower decline in composite IC scores of five domains over one year (βhigh 1.60; 95% CI 0.06– 3.15). The low- and high-intermediate IF1 quartiles were cross-sectionally associated with greater locomotion (βlow-intermediate, 2.72; 95% CI 0.36–5.08) and vitality scores (βhigh-intermediate, 1.59; 95% CI 0.06–3.12), respectively.
Conclusion This study is the first to report circulating IF1 levels as a mitochondrial-related biomarker associated with IC composite scores in cross-sectional and prospective analyses in community-dwelling older adults. Further research is needed to confirm these findings, in particular, to determine a potential cut-off defining optimal plasma IF1 levels and to unravel the potential mechanisms that can explain these associations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The present work was performed in the context of the Inspire Program, a research platform supported by grants from the Region Occitanie/Pyrenees-Mediterranee (Reference number: 1901175) and the European Regional Development Fund (ERDF) (Project number: MP0022856). Funding was received from Alzheimer Prevention in Occitania and Catalonia (APOC Chair of Excellence - Inspire Program) and Saint Louis University. The MAPT study was supported by grants from the Gerontopole of Toulouse, the French Ministry of Health (PHRC 2008, 2009), Pierre Fabre Research Institute (manufacturer of the omega-3 supplement), ExonHit Therapeutics SA, and Avid Radiopharmaceuticals Inc. The promotion of this study was supported by the University Hospital Center of Toulouse. The data sharing activity was supported by the Association Monegasque pour la Recherche sur la maladie d Alzheimer (AMPA) and the INSERM-University of Toulouse III UMR 1295 (CERPOP) Research Unit.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the French Ethics Committee located in Toulouse (Comite de Protection des Personnes SOOM II) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# members are listed in the acknowledgements
E-mails : Yves Rolland: rolland.y{at}chu-toulouse.fr
Souad Najib: souad.najib{at}inserm.fr
Mikaël Croyal: mikael.Croyal{at}univ-nantes.fr
Bertrand Perret : bertrand.perret{at}inserm.fr
Nabila Jabrane-Ferrat : nabila.jabrane-ferrat{at}inserm.fr
Hicham El Costa: hicham.el-costa{at}inserm.fr
Sophie Guyonnet: guyonnet.s{at}chu-toulouse.fr
Bruno Vellas: vellas.b{at}chu-toulouse.fr
Philipe de Souto Barreto: philipebarreto81{at}yahoo.com.br
Data Availability
All data produced in the present study are available upon reasonable request to the authors
